Form 4: Arvinas Director Sunil Agarwal Granted Significant Equity Awards

Arvinas, Inc. Director Sunil Agarwal was granted 16,025 restricted stock units and 23,105 stock options as part of his compensation, aligning his interests with shareholder value.

Summary

• Sunil Agarwal, a Director of Arvinas, Inc., was granted 16,025 Restricted Stock Units (RSUs) and 23,105 stock options on June 25, 2025.
• The RSUs represent a contingent right to receive one share of common stock for no consideration.
• The stock options have an exercise price of $7.8 per share and expire on June 24, 2035.
• Both the RSUs and stock options are scheduled to vest in full on the earlier of June 25, 2026, or the first meeting of the board of directors held after the next annual meeting of stockholders, contingent on Mr. Agarwal's continued service.
• Following these transactions, Mr. Agarwal beneficially owns 30,166 shares of common stock directly and 23,105 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is a positive event for corporate governance and alignment of interests, indicating stability and a standard compensation practice. It's not a major catalyst but reinforces positive structural elements.

Positives

• The grant of RSUs and stock options to Director Sunil Agarwal aligns his financial interests with the long-term performance of Arvinas, Inc.
• Equity awards serve as a retention mechanism, incentivizing continued service and dedication from a key board member.
• The vesting schedule encourages a long-term perspective on company growth and shareholder value creation.

Negatives

• The issuance of new equity awards could lead to potential future dilution for existing shareholders upon vesting and exercise, although this is a standard component of executive and director compensation.

Risks

• Vesting of the granted RSUs and stock options is subject to Sunil Agarwal's continued service with Arvinas, Inc. on the vesting date.

Future Outlook

The equity awards are designed to vest in the future, specifically on the earlier of June 25, 2026, or the first board meeting after the next annual stockholders' meeting, contingent on the director's continued service. This indicates a commitment to long-term retention and performance alignment.

Industry Context

This is a routine compensation event for a director, common across publicly traded companies in various industries, including biotechnology, to align director interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of equity awards (RSUs and stock options) to non-employee directors is a standard practice in the biotechnology and pharmaceutical industries, similar to compensation structures at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which often use equity to incentivize long-term commitment and performance.
• The vesting schedule, tied to continued service and a specific future date or corporate event (annual meeting), is also a common mechanism to ensure director retention and alignment with corporate governance best practices.
• The exercise price of $7.8 for the options would be compared to the stock price on the grant date to assess if they were granted at-the-money, which is typical for incentive options.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Sunil Agarwal, a Director of Arvinas, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of equity awards, but also benefits from enhanced alignment of director interests with long-term company performance.
• Employees: No direct impact mentioned, but standardizes compensation practices for leadership.
• Management: Reinforces the company's compensation structure for its board members.

Next Steps

• The RSUs and stock options are expected to vest on the earlier of June 25, 2026, or the first meeting of the board of directors held after the next annual meeting of stockholders, subject to continued service.
• The stock options will expire on June 24, 2035, if not exercised.

Key Dates

Recommendation

Keywords

Arvinas Inc., ARVN, SEC Form 4, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Insider Transaction, Sunil Agarwal, Corporate Governance